Bailard’s Gyre Therapeutics GYRE Stock Holding History

Bailard’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-135	Closed	-$442K	–	233
2013 Q4	$442K	Hold	135	–	–	0.07%	146
2013 Q3	$566K	Hold	135	–	–	0.11%	145
2013 Q2	$455K	Buy	+135	New	+$514K	0.08%	138

Other funds holding GYRE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bailard's GYRE Position: Q1 2014 in Review

Bailard sold out of Gyre Therapeutics (GYRE) in Q1 2014, closing a stake of 135 shares — an estimated $442K sold.

Bailard first reported a position in GYRE in Q2 2013 and held it in 3 quarters. The position peaked at $566K in Q3 2013. 64 funds tracked by Wall St. Rank hold GYRE as of Q1 2014.

Bailard reported no remaining Gyre Therapeutics position as of Q1 2014 after selling out during the quarter.
Bailard sold 135 Gyre Therapeutics shares in Q1 2014, an estimated $442K.
Bailard first reported a position in Gyre Therapeutics in Q2 2013 and held it in 3 quarters.
Bailard's Gyre Therapeutics position peaked at $566K in Q3 2013.
64 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2014.

Based on Bailard's 13F filing for Q1 2014, filed 30 Apr 2014.